On March 13, 2026, IB Acquisition Corp. disclosed a joint marketing agreement with a Fortune 100 tech company to enhance AI-driven drug discovery efforts. This is a significant development for the company, indicating strategic collaborative plans to integrate technologies in the healthcare sector.